DrugDashboards

Ceftriaxone

Ceftriaxone · CEFTRIAXONE SODIUM 1 g/1 · Injection, Powder, For Solution · Intramuscular; Intravenous · WG Critical Care, LLC

NDC 44567-0701-25 · 25 VIAL in 1 CARTON / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL · ANDA · View full market →

The short version

6 companies supply this market — a reasonable cushion if one runs into trouble. The price has held steady around $1.44 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$1.44per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicare Part B pays (ASP+6%)$0.4040per billing unit (250 MG)HCPCS J0696 · Jul 1, 2026
  • Part D plans paid (avg)$12.85per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal contracts pay (FSS)$1.36per unitWG Critical Care, LLC · Jun 15, 202494% of what pharmacies pay — a deeper discount than 52% of drugs with this benchmark

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$1.00$2.00$3.00Jun 2015Sep 2026$1.44
39 price points · per EASource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$2.70
Reported to Texas DSHS · 2026 annual filing · WG Critical Care

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 250 MG
$0.404
HCPCS J0696 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$663,680
160,073 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

10Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for ceftriaxone (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $114.40 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA065329
TE code
AP
Approval date
Jul 24, 2008
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Ceftriaxone (Injection, Powder, For Solution)

LabelerStrengthFirst seenLast seen
WG Critical Care, LLCCEFTRIAXONE SODIUM 2 g/1Jul 15, 2026Sep 3, 2026
Civica, Inc.CEFTRIAXONE SODIUM 2 g/1Jul 15, 2026Sep 2, 2026
Civica, Inc.CEFTRIAXONE SODIUM 1 g/1Jul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCCEFTRIAXONE SODIUM 1 g/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.CEFTRIAXONE SODIUM 250 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.CEFTRIAXONE SODIUM 500 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.CEFTRIAXONE SODIUM 1 g/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.CEFTRIAXONE SODIUM 10 g/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.CEFTRIAXONE SODIUM 2 g/1Jul 15, 2026Sep 2, 2026
Proficient Rx LPCEFTRIAXONE SODIUM 2 g/1Jul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsCEFTRIAXONE SODIUM 2 g/1Jul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsCEFTRIAXONE SODIUM 1 g/1Jul 15, 2026Sep 2, 2026
WG Critical Care, LLCCEFTRIAXONE SODIUM 500 mg/1Jul 15, 2026Sep 2, 2026
WG Critical Care, LLCCEFTRIAXONE SODIUM 10 g/1Jul 15, 2026Sep 2, 2026
WG Critical Care, LLCCEFTRIAXONE SODIUM 1 g/1Jul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ceftriaxone — NDC 44567-0701-25," retrieved September 3, 2026, https://drugdashboards.com/drug/44567070125.

Free to cite with attribution — see how the data is put together.